X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2572) 2572
Newsletter (82) 82
Newspaper Article (26) 26
Book Chapter (18) 18
Dissertation (10) 10
Magazine Article (6) 6
Publication (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vemurafenib (2558) 2558
melanoma (1534) 1534
humans (1429) 1429
oncology (1085) 1085
braf (773) 773
mutation (756) 756
cancer (696) 696
melanoma - drug therapy (688) 688
proto-oncogene proteins b-raf - genetics (657) 657
male (595) 595
female (581) 581
metastatic melanoma (574) 574
dabrafenib (503) 503
proto-oncogene proteins b-raf - antagonists & inhibitors (501) 501
middle aged (466) 466
survival (462) 462
melanoma - genetics (434) 434
melanoma - pathology (423) 423
metastasis (379) 379
care and treatment (357) 357
dermatology (354) 354
aged (353) 353
skin neoplasms - drug therapy (348) 348
ipilimumab (346) 346
open-label (346) 346
adult (334) 334
mutations (321) 321
antineoplastic agents - therapeutic use (318) 318
research (308) 308
cell line, tumor (288) 288
animals (282) 282
resistance (278) 278
immunotherapy (267) 267
skin neoplasms - pathology (267) 267
tumors (257) 257
sulfonamides - therapeutic use (249) 249
therapy (246) 246
indoles - therapeutic use (244) 244
improved survival (238) 238
drug therapy (232) 232
treatment outcome (232) 232
genetic aspects (229) 229
gene mutations (227) 227
kinases (224) 224
mek inhibition (216) 216
protein kinase inhibitors - therapeutic use (208) 208
inhibition (206) 206
trametinib (206) 206
skin neoplasms - genetics (204) 204
neoplasms (200) 200
analysis (199) 199
sulfonamides - pharmacology (198) 198
chemotherapy (196) 196
proto-oncogene proteins b-raf - metabolism (191) 191
acquired-resistance (187) 187
indoles - pharmacology (187) 187
multicenter (187) 187
antineoplastic agents - pharmacology (186) 186
pharmacology & pharmacy (186) 186
cell biology (181) 181
braf inhibitor (177) 177
targeted therapy (175) 175
health aspects (173) 173
medicine, research & experimental (172) 172
melanoma - metabolism (172) 172
protein kinase inhibitors - pharmacology (172) 172
aged, 80 and over (171) 171
antineoplastic agents - adverse effects (164) 164
mice (163) 163
sulfonamides - adverse effects (162) 162
drug resistance (160) 160
patients (159) 159
indoles - adverse effects (156) 156
expression (144) 144
melanoma - secondary (143) 143
activation (142) 142
prognosis (141) 141
molecular targeted therapy (140) 140
apoptosis (137) 137
metastases (137) 137
skin cancer (137) 137
clinical trials (136) 136
antineoplastic combined chemotherapy protocols - therapeutic use (132) 132
pathway (130) 130
retrospective studies (129) 129
efficacy (124) 124
malignant-melanoma (124) 124
neoplasm metastasis (124) 124
sulfonamides - administration & dosage (124) 124
braf mutation (123) 123
cancer therapies (120) 120
cobimetinib (116) 116
development and progression (116) 116
indoles - administration & dosage (116) 116
inhibitors (116) 116
pathology (113) 113
dosage and administration (112) 112
nivolumab (112) 112
abridged index medicus (111) 111
proteins (111) 111
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2589) 2589
French (57) 57
German (35) 35
Russian (10) 10
Spanish (8) 8
Polish (7) 7
Czech (5) 5
Korean (4) 4
Chinese (3) 3
Dutch (3) 3
Japanese (3) 3
Portuguese (2) 2
Swedish (2) 2
Hungarian (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


La revue de medecine interne, ISSN 0248-8663, 06/2019, Volume 40, p. A177
La maladie d'Erdheim Chester est une histiocytose non-largerhansienne rare du groupe L. Elle peut toucher tous les organes et en particulier les os et... 
Vemurafenib
Journal Article
Cancer, ISSN 0008-543X, 2/2019, Volume 125, Issue 3, pp. 463 - 472
The combination of vemurafenib, carboplatin, and paclitaxel demonstrated an acceptable safety profile in patients with advanced cancers and BRAFV600 mutations.... 
paclitaxel | carboplatin | vemurafenib | BRAF mutation
Journal Article
Nature (London), ISSN 1476-4687, 2018, Volume 558, Issue 7711, pp. 605 - 609
Reprogramming of mRNA translation has a key role in cancer development and drug resistance(1). However, the molecular mechanisms that are involved in this... 
CELLS | MELANOMA | INHIBITION | TRANSFER-RNAS | KINASE | IMPROVED SURVIVAL | MUTATIONS | HUMAN CANCER | VEMURAFENIB | RIBOSOME | MULTIDISCIPLINARY SCIENCES | Phosphorylation | Humans | Melanoma, Experimental - drug therapy | Male | Uridine - genetics | RNA, Messenger - metabolism | Vemurafenib - therapeutic use | Melanoma - genetics | RNA, Transfer - genetics | Carrier Proteins - chemistry | Female | Codon - genetics | Codon - drug effects | RNA, Transfer - chemistry | Uridine - chemistry | Signal Transduction | RNA, Transfer - metabolism | RNA, Messenger - genetics | Melanoma, Experimental - pathology | Melanoma - pathology | Mice, SCID | Vemurafenib - pharmacology | Zebrafish - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Mechanistic Target of Rapamycin Complex 2 - metabolism | Drug Resistance, Neoplasm - genetics | Animals | Carrier Proteins - metabolism | Melanoma, Experimental - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Mice, Inbred NOD | Protein Biosynthesis - drug effects | Uridine - metabolism | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Codon | Oncology, Experimental | Melanoma | Research | Genetic translation | Cancer | Enzymes | Physiological aspects | Development and progression | Protein biosynthesis | Transfer RNA | Short term | Therapy | Transformation | Genomes | mRNA | Kinases | Proteins | Signal transduction | Translation | Cell survival | tRNA | MAP kinase | Pharmacology | Decoding | Metabolism | Gene expression | Chemical compounds | Survival | Molecular chains | 1-Phosphatidylinositol 3-kinase | Signaling | Molecular modelling | Protein synthesis | Uridine | Glycolysis | Mutation
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 6, pp. 536 - 542
PurposeDetection of specific molecular alterations in tumors guides the selection of effective targeted treatment of patients with several types of cancer.... 
CELL LUNG-CANCER | TRIAL | OVEREXPRESSION | AMPLIFICATION | GENE | ONCOLOGY | THYROID-CARCINOMA | HER2 EXPRESSION | BRAF V600E MUTATION | METASTATIC COLORECTAL-CANCER | VEMURAFENIB
Journal Article
OncoImmunology, ISSN 2162-4011, 01/2013, Volume 2, Issue 1
To optimally integrate targeted kinase inhibitors and immunotherapies in the treatment of melanoma, it will be critical to understand how BRAF V600E mutational... 
vemurafenib | melanoma | MHC | BRAF | Vemurafenib | Melanoma | Research Paper
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 3, pp. 611 - 621
Abstract Background & Aim Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase... 
Hematology, Oncology and Palliative Medicine | Vemurafenib | Symptomatic brain metastases | Tumour regression | BRAF inhibitor | Safety | Advanced melanoma | BRAF mutation
Journal Article
JAMA Dermatology, ISSN 2168-6068, 10/2015, Volume 151, Issue 10, pp. 1103 - 1109
IMPORTANCE The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of metastatic melanoma have been well... 
DABRAFENIB | METASTATIC MELANOMA | MULTICENTER | THERAPY | KERATOSIS | ERUPTION | IMPROVED SURVIVAL | RAF INHIBITORS | OPEN-LABEL | VEMURAFENIB | DERMATOLOGY
Journal Article
The Journal of experimental medicine, ISSN 1540-9538, 2014, Volume 211, Issue 4, pp. 669 - 683
Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized by the accumulation of CD207+ dendritic cells (DCs) in... 
MEDICINE, RESEARCH & EXPERIMENTAL | ERDHEIM-CHESTER DISEASE | HISTIOCYTOSIS | THERAPY | GENE | BRAF V600E MUTATION | BIRBECK GRANULES | STEADY-STATE | LEUKEMIA | IMMUNOLOGY | LANGERHANS CELLS | VEMURAFENIB
Journal Article
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2013, Volume 110, Issue 45, pp. 18226 - 18231
Inhibitors of BRAF protein kinase, such as Vemurafenib and Dabrafenib, have shown remarkable antitumor activity in patients with BRAF mutant melanoma. However,... 
Vemurafenib | LKB1 | Biological Sciences
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 18, pp. 14567 - 14579
Melanoma is a current worldwide problem, as its incidence is increasing. In the last years, several studies have shown that melanoma cells display high levels... 
Vemurafenib | Starvation | Galectin-3 | Autophagy | Melanoma
Journal Article
Molecular & cellular oncology, ISSN 2372-3556, 2018, Volume 5, Issue 5, p. e1497862
Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD... 
USP28/BRAF/Melanoma/Vemurafenib resistance
Journal Article
by Zehir, Ahmet and Benayed, Ryma and Shah, Ronak H and Syed, Aijazuddin and Middha, Sumit and Kim, Hyunjae R and Srinivasan, Preethi and Gao, Jianjiong and Chakravarty, Debyani and Devlin, Sean M and Hellmann, Matthew D and Barron, David A and Schram, Alison M and Hameed, Meera and Dogan, Snjezana and Ross, Dara S and Hechtman, Jaclyn F and DeLair, Deborah F and Yao, JinJuan and Mandelker, Diana L and Cheng, Donavan T and Chandramohan, Raghu and Mohanty, Abhinita S and Ptashkin, Ryan N and Jayakumaran, Gowtham and Prasad, Meera and Syed, Mustafa H and Rema, Anoop Balakrishnan and Liu, Zhen Y and Nafa, Khedoudja and Borsu, Laetitia and Sadowska, Justyna and Casanova, Jacklyn and Bacares, Ruben and Kiecka, Iwona J and Razumova, Anna and Son, Julie B and Stewart, Lisa and Baldi, Tessara and Mullaney, Kerry A and Al-Ahmadie, Hikmat and Vakiani, Efsevia and Abeshouse, Adam A and Penson, Alexander V and Jonsson, Philip and Camacho, Niedzica and Chang, Matthew T and Won, Helen H and Gross, Benjamin E and Kundra, Ritika and Heins, Zachary J and Chen, Hsiao-Wei and Phillips, Sarah and Zhang, Hongxin and Wang, Jiaojiao and Ochoa, Angelica and Wills, Jonathan and Eubank, Michael and Thomas, Stacy B and Gardos, Stuart M and Reales, Dalicia N and Galle, Jesse and Durany, Robert and Cambria, Roy and Abida, Wassim and Cercek, Andrea and Feldman, Darren R and Gounder, Mrinal M and Hakimi, A Ari and Harding, James J and Iyer, Gopa and Janjigian, Yelena Y and Jordan, Emmet J and Kelly, Ciara M and Lowery, Maeve A and Morris, Luc G T and Omuro, Antonio M and Raj, Nitya and Razavi, Pedram and Shoushtari, Alexander N and Shukla, Neerav and Soumerai, Tara E and Varghese, Anna M and Yaeger, Rona and Coleman, Jonathan and Bochner, Bernard and Riely, Gregory J and Saltz, Leonard B and Scher, Howard I and Sabbatini, Paul J and Robson, Mark E and Klimstra, David S and Taylor, Barry S and Baselga, Jose and Schultz, Nikolaus and Hyman, David M and Arcila, Maria E and Solit, David B and Ladanyi, Marc and Berger, Michael F
Nature medicine, ISSN 1546-170X, 2017, Volume 23, Issue 6, pp. 703 - 713
Journal Article
Endocrine-Related Cancer, ISSN 1351-0088, 01/2018, Volume 25, Issue 1, pp. 99 - 109
Journal Article